SOST and chronic kidney disease: Fig 1 shows serum sclerostin and DKK1 levels across CKD stages. In patients with chronic kidney disease treated with dialysis, sclerostin was approximately 2.5-fold higher than in non-CKD controls. Serum DKK1 levels, conversely were approximately 2-fold lower in dialysis patients as compared to non-CKD controls. S1 Fig shows temporal aspects of disordered mineral metabolism and sclerostin in CKD stage 1-5D.